The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells combined with targeted therapy and PD-1 monoclonal antibody in first-line treatment of patients with hepatocellular carcinoma.
Patients should sign informed consent form voluntarily before the trail and comply with the requirements of this study.
Age 18 years up to the age of 75 (≤75), gender unlimited.
Hepatocellular Carcinoma diagnosed according to the 2018 edition of the EASL guidelines.
BCLC stage B or C.
Patients combined with HAV, HEV, HIV or other infectious diseases.
Acute infections, gastrointestinal bleeding, etc. occurred within 30 days before screening.
Women who are pregnant (urine/blood pregnancy test positive) or lactating; patients with severe autoimmune diseases; patients with uncontrolled infectious diseases.
Major organs dysfunction.
Beijing 302 Hospital
Lead sponsor
Chinese Academy of Medical Sciences
Collaborator
Beijing GD Initiative Cell Therapy Technology Co., Ltd.
Collaborator